ArticleOncogene2014
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.Cancers · 2022Article
- Review
- Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18.Journal of molecular histology · 2021Article
- SynLeGG: analysis and visualization of multiomics data for discovery of cancer 'Achilles Heels' and gene function relationships.Nucleic acids research · 2021Article
- AMolecular cancer research : MCR · 2020Article
- Concordance of Genomic Alterations between Circulating Tumor DNA and Matched Tumor Tissue in Chinese Patients with Breast Cancer.Journal of oncology · 2020Article
- Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.Journal of cellular physiology · 2019Observational
- PATRI, a Genomics Data Integration Tool for Biomarker Discovery.BioMed research international · 2018Article
- Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.Oncogene · 2017Article
- Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Disease markers · 2017Review
- Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.Oncotarget · 2016Article
- The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis.Oncogene · 2015Article
- A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- miR-214 as a key hub that controls cancer networks: small player, multiple functions.The Journal of investigative dermatology · 2015Review
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.The Journal of pathology · 2014Article
- Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Oncogene · 2014Article
- From integrative genomics to therapeutic targets.Cancer research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Funding
Abstract
Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2+ve breast cancers are distinguished from ER+ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2+ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2+ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2+ve breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.